

PH-1

## Pharmacology of Letrozole

---

**Ajay S. Bhatnagar, PhD**  
**Scientific Expert, Femara®**  
**Novartis Pharma AG**  
**Basel, Switzerland**





PH-2

## Presentation

---

- Mechanism of action of aromatase inhibitors
- Intratumoral aromatase
- Results published after submission of Femara® NDA in 1996





PH-5

## Letrozole

---

- A highly potent aromatase inhibitor in vitro and in vivo
- Very selective in its inhibition of aromatase
- As effective as oophorectomy in inducing estrogen deprivation
- Shows maximal antitumor efficacy in the DMBA and NMU models
- 1 to 2 orders of magnitude more efficacious than anastrozole in endocrine and antitumor efficacy
- Prevents the appearance of spontaneous mammary tumors in rats

 NOVARTIS

14


PH-6

## Commercially Available Aromatase Inhibitors

---

Aminoglutethimide	Orimeten®	Novartis
Fadrozole	Afema®	Novartis
Letrozole	Femara®	Novartis
Anastrozole	Arimidex®	AstraZeneca
Formestane	Lentaron®	Novartis
Exemestane	Aromasin®	Pharmacia & Upjohn

 NOVARTIS







14 PH-8


### Sources of Aromatase

Placental microsomes	Human, cell-free
Ovarian tissue	Rodent, endocrine, cellular
Breast adipose fibroblasts	Human, endocrine, cellular
MCF-7Ca	Human breast cancer, cellular
JEG-3	Human choriocarcinoma, cellular

NOVARTIS







PH-14

## Conclusions

**Letrozole is**

- A more potent aromatase inhibitor than anastrozole in the preclinical setting
- A more effective aromatase inhibitor than anastrozole in a human setting
- A more effective anti-tumor agent than both anastrozole and the antiestrogen tamoxifen in an animal tumor model

NOVARTIS